| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.34 | 5e-22 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.41 | 8e-18 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.26 | 4e-13 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-09 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 4e-09 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.19 | 7e-09 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-07 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.26 | 4e-07 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-06 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.16 | 7e-06 |